The RNA-Based Therapeutics and Vaccine Technologies Market is projected to grow from USD 1.8 billion in 2026 to USD 3.2 billion by 2031, reflecting a 12.2% CAGR.
Therapeutics and vaccines based on RNA utilise ribonucleic acid for the direct regulation of gene expression or production of therapeutic proteins in the body. RNA-based pharmacological treatment includes mRNA vaccines, RNA interference (RNAi), and antisense oligonucleotides. The success of the mRNA COVID-19 vaccines validates mRNA technology, as well as accelerating research in oncology, rare diseases and infectious diseases. New delivery systems & AI-assisted design advancements further improve efficacy and allow for more global applications.
Continuous advancements in RNA technologies (mRNA, siRNA, antisense technologies) are leading to more precise and scalable therapeutics. The ability to develop drugs faster and modulate genes more effectively is being enhanced by numerous research breakthroughs and expanding clinical applications of RNA technologies. Consequently, RNA technologies will be positioned as a critical component of future therapeutics and vaccine development.
Personalised medicine is growing in popularity due to its ability to offer patient-specific therapies that address their genetic and molecular characteristics. This is particularly useful in oncology and rare diseases, where many patients do not respond well to standard treatments. The adoption of RNA-based therapies by healthcare systems globally is increasing as these therapies can improve treatment outcomes, reduce adverse effects, and provide more precise treatment.
Governments, pharma companies, and investors are funding a significant amount of RNA-based research and development. Post-pandemic, many funding sources are providing increasing amounts of venture capital and entering into partnerships to support the innovation and commercialisation of therapies. This funding will help to accelerate the current clinical trials for RNA-based therapies, expand the number of RNA-based therapies being developed, and enhance the manufacturing capabilities of RNA therapeutics, thereby providing substantial support to overall growth trends in the RNA-based market.
The increasing prevalence of infectious diseases, cancers, and inherited genetic disorders is driving demand for advanced therapeutic solutions. Compared to traditional therapies, RNA technologies have been shown to provide faster and more effective treatment options, which is particularly important for addressing unmet medical needs and emerging pathogens. For these reasons, RNA technologies will continue to play an important role in modern medicine and support long-term market growth.
The market faces challenges such as delivery complexity, high development costs, and regulatory hurdles. Stability and targeted delivery of RNA molecules remain key technical barriers. However, opportunities lie in AI-driven drug design, next-generation delivery systems, and expanding applications in oncology and gene therapy. Continued innovation and clinical success are expected to unlock significant long-term growth.
June 2025: In 2025, BioNTech strengthened its position in RNA therapeutics by acquiring CureVac, significantly expanding its mRNA technology capabilities, intellectual property portfolio, and manufacturing capacity. This strategic move enhances BioNTech’s development of next-generation mRNA-based cancer immunotherapies and reinforces industry consolidation in RNA platonic.
The market is segmented by product type, RNA type, application and geography.
As a well-established category of RNA-based therapeutics and vaccine technologies, RNA-based vaccines are expected to continue their leading position in this market segment due to the success of mRNA vaccines for COVID-19. In addition to COVID-19, there has been a continued expansion of RNA vaccines into Infectious Disease and Cancer Therapeutics (see below). The ability to rapidly develop and scale, as well as to generate robust immune responses, are some of the reasons for the current growth and projected expansion in the number of RNA vaccines available in the near future, with improved thermostability and innovative delivery systems.
As the most versatile type of RNA with proven success in clinical trials, mRNA is a market leader. mRNA instructs cells to produce therapeutic proteins or antigens and can be used to create vaccines as well as target specific actions of disease (e.g., Cancer). In addition to continuing to expand the use of mRNA-based therapeutics/vaccines into new uses for infectious diseases, mRNA technology will begin more aggressively to move into the areas of cancer immunotherapy and rare genetic diseases due to continuous innovation in the delivery platforms.
Cancer is a key area of application for RNA-based therapeutics because of the ability of RNA-based therapies to provide targeted treatment through modification of gene expression and stimulation of the immune system in an effort to promote tumour destruction and/or prevention. Because of this ability, by 2025, mRNA cancer vaccines and RNA-based therapeutics will be growing rapidly in clinical trials. The expansion of personal cancer treatment and precision therapy will continue to drive the rapid growth of this segment.
Due to its strong biotechnology infrastructure and high level of investment in RNA research, North America is dominating the market. In addition, mRNA vaccines were adopted quickly in North America, with the presence of many of the world's leading manufacturers of pharmaceuticals. The other factors driving growth are the extensive number of clinical trials and the regulatory support provided in North America. Therefore, North America is the largest global market.
In South America, there is a gradual increase in growth due to improvements in healthcare infrastructure and greater awareness of advanced therapies. In addition, there are increasing demands for effective treatments for infectious diseases and increasing research capabilities, which will also support the adoption of RNA-based products.
Europe is showing significant growth that is supported by healthcare systems that are highly developed and have government funding for biotechnology research. The increased importance of personalised medicine and the cooperation between research universities and pharmaceutical companies will continue to support the growth of RNA-based medicines and RNA-based vaccines.
The MEA region is an emerging market with increased investments in healthcare and biotechnology. Increasingly, there is an adoption of RNA-based therapeutics due to international collaboration and the ability to access advanced therapy.
Asia-Pacific is the fastest-growing area of the world because of an expanding number of biopharmaceutical companies and an increase in healthcare spending. In addition, countries like China, India and Japan are aggressively developing RNA technology. Furthermore, government initiatives and increased clinical research will accelerate the growth of the market.
Moderna
BioNTech
CureVac
Alnylam Pharmaceuticals
Arrowhead Pharmaceuticals
Ionis Pharmaceuticals
Translate Bio
GSK
Sanofi
Arcturus Therapeutics
BioNTech is a global biotechnology company that develops and commercialises new mRNA-based therapeutics and immunotherapies. The company gained worldwide visibility as a result of its partnership with Pfizer to develop the mobile RNA vaccine for COVID-19. BioNTech plans to develop additional personalised cancer vaccines that use mRNA to stimulate the patient's own immune system to attack their own tumours. The company has dedicated significant investments to developing next-generation mRNA platform technologies, including cell-based therapies and artificial intelligence-derived drug candidates. Its robust pipeline of oncology-related products will greatly assist in driving future growth.
Alnylam Pharmaceuticals has established itself as a pioneer in the development and commercialisation of RNA interference (RNAi) therapies utilising small interfering RNAs (siRNAs). The company's initial focus has been on developing therapies for rare and/or genetic diseases, and through its commercial introduction of multiple siRNA-based therapies, Alnylam is currently the leader in the siRNA-based therapeutic market. In 2025, Alnylam has committed itself to expanding its pipeline in the treatment of patients with cardiometabolic, hepatic and/or neurological diseases. In addition, Alnylam has invested a significant amount of resources in the development of proprietary technologies that enhance the ability to target a specific gene in order to enhance therapeutic outcomes. Alnylam is well-positioned for significant growth and innovation through its extensive clinical portfolio, regulatory approvals, and strategic partnerships with world-class pharmaceutical companies relating to RNA-based therapeutics, particularly in the areas of precision medicine and the treatment of rare diseases.
Moderna is one of the leading biopharmaceutical companies developing therapeutic and preventive medications using messenger RNA (mRNA) technologies. The company's global presence has grown significantly since being recognised for its COVID-19 vaccine; however, the expansion of its product line now also includes products in oncology, rare disease and respiratory indications. In 2025, the development of mRNA-based personalised cancer vaccines will continue, as well as further research into the co-administration of mRNA-based therapeutic agents and advances in the use of lipid nanoparticles as mRNA delivery systems. Moderna's vast research and development capacity, substantial manufacturing capabilities and significant partnerships effectively place it among the leading RNA therapeutic companies in the world.
| Report Metric | Details |
|---|---|
| Total Market Size in 2026 | USD 1.8 billion |
| Total Market Size in 2031 | USD 3.2 billion |
| Forecast Unit | Billion |
| Growth Rate | 12.2% |
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Segmentation | Product Type, Rna Type, Application, Geography |
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies |
|